Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced the grant of stock options to nine new employees. These options allow the purchase of 109,000 shares of common stock at an exercise price of $2.82 per share, which was the closing price on October 1, 2024.
The grants were made under the Nasdaq inducement grant exception, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over four years, with 25% vesting on the one-year anniversary of each employee's hire date, and the remaining shares vesting quarterly over the following three years in equal amounts. Vesting is contingent on continued employment or service provision to Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM), un'azienda biofarmaceutica focalizzata sullo sviluppo di nuovi farmaci per il cancro, ha annunciato la concessione di opzioni azionarie a nove nuovi dipendenti. Queste opzioni consentono l'acquisto di 109.000 azioni ordinarie a un prezzo di esercizio di $2,82 per azione, che era il prezzo di chiusura dell'1 ottobre 2024.
Le concessioni sono state effettuate nell'ambito dell'eccezione dell'induzione Nasdaq, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le opzioni azionarie si matureranno in quattro anni, con il 25% che matura al primo anniversario della data di assunzione di ciascun dipendente, e le rimanenti azioni che maturano trimestralmente nei tre anni successivi in quantità uguali. La maturazione è subordinata al mantenimento dell'impiego o della fornitura di servizi a Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM), una compañía biofarmacéutica enfocada en desarrollar nuevos medicamentos contra el cáncer, ha anunciado la concesión de opciones sobre acciones a nueve nuevos empleados. Estas opciones permiten la compra de 109,000 acciones ordinarias a un precio de ejercicio de $2.82 por acción, que fue el precio de cierre el 1 de octubre de 2024.
Las concesiones se realizaron bajo la excepción de concesión por inducción de Nasdaq, de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4). Las opciones sobre acciones se adquirirán durante cuatro años, con el 25% adquiriéndose en el primer aniversario de la fecha de contratación de cada empleado, y las acciones restantes adquiriéndose trimestralmente durante los siguientes tres años en cantidades iguales. La adquisición está sujeta a la continuación del empleo o prestación de servicios para Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM)는 새로운 암 의약품 개발에 중점을 둔 생물 제약 회사로, 아홉 명의 신입 사원에게 주식 매수선택권을 부여했다고 발표했습니다. 이 옵션은 109,000주의 보통주를 주당 $2.82의 행사 가격으로 구매할 수 있게 해주며, 이는 2024년 10월 1일의 종가였습니다.
이 부여는 Nasdaq 유인 부여 예외에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 주식 매수선택권은 4년 동안 배분됩니다, 각 직원의 고용일 1주년 기념일에 25%가 배분되며, 나머지 주식은 다음 3년 동안 분기별로 동일한 양으로 배분됩니다. 배분은 Verastem Oncology에 대한 고용 유지 또는 서비스 제공에 따라 달라집니다.
Verastem Oncology (Nasdaq: VSTM), une entreprise biopharmaceutique spécialisée dans le développement de nouveaux médicaments contre le cancer, a annoncé l'octroi de stock-options à neuf nouveaux employés. Ces options permettent l'achat de 109,000 actions ordinaires à un prix d'exercice de $2,82 par action, qui était le prix de clôture au 1er octobre 2024.
Les octrois ont été effectués dans le cadre de l'exception d'octroi d'incitations de Nasdaq, conformément à la règle de cotation Nasdaq 5635(c)(4). Les stock-options seront acquises sur quatre ans, avec 25% acquises à la première date anniversaire de l'embauche de chaque employé, et les actions restantes acquises trimestriellement pendant les trois années suivantes en montants égaux. L'acquisition est conditionnée par la poursuite de l'emploi ou de la prestation de services chez Verastem Oncology.
Verastem Oncology (Nasdaq: VSTM), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Krebsmedikamente konzentriert, hat die Gewährung von Aktienoptionen an neun neue Mitarbeiter bekannt gegeben. Diese Optionen ermöglichen den Kauf von 109.000 Aktien zu einem Ausübungspreis von $2,82 pro Aktie, der am 1. Oktober 2024 der Schlusskurs war.
Die Gewährungen erfolgten unter der Nasdaq-Induktionsausnahme, gemäß der Nasdaq-Listingsregel 5635(c)(4). Die Aktienoptionen werden über vier Jahre angesammelt, wobei 25 % am ersten Jahrestag des Anstellungsdatums jedes Mitarbeiters anfallen und die verbleibenden Aktien in gleichen Mengen vierteljährlich in den folgenden drei Jahren anfallen. Das Ansammeln ist an die Fortsetzung der Beschäftigung oder der Serviceerbringung für Verastem Oncology gebunden.
- Attraction of new talent with stock options as incentives
- Alignment of employee interests with company performance through equity grants
- Potential dilution of existing shareholders' equity
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241007980498/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications and Investor Relations
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
FAQ
How many shares of Verastem Oncology (VSTM) stock options were granted to new employees?
What is the exercise price of the stock options granted by Verastem Oncology (VSTM)?
What is the vesting schedule for the Verastem Oncology (VSTM) stock options granted to new employees?
Under which Nasdaq rule did Verastem Oncology (VSTM) grant these stock options?
